Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the
Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in
children, adolescents and young adults with refractory ADV infection post Allogeneic
Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or
post solid organ transplant.
Funding Source: FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborators:
Children's Hospital of Philadelphia Johns Hopkins University Medical College of Wisconsin Nationwide Children's Hospital University of California, San Francisco University of Colorado, Denver